Based on data collected from different sources by our team,
there are indicators that suggest that this company is no longer active. However, this information may not be accurate.
If you believe this information should be updated, please .
For more details, you can read our .
Xconomy: Twist Bioscience IPO Hauls In $70M for DNA Synthesis Technology
undefined
Jul 25, 2018
officesnapshots.com
Office Tour: Twist Bioscience Offices - Tel Aviv
#Customers #Partners
Oct 21, 2016
www.globes.co.il
US co Twist Bioscience buys Israel's Genome Compiler
#Acquisition #Partners
About
Twist Bioscience Corporation's expertise is synthetic DNA. The company developed a proprietary, semiconductor-based synthetic-DNA manufacturing process featuring a 10,000-well silicon platform capable of producing synthetic biology tools such as oligonucleotides, genes, pathways, chassis, and genomes. By synthesizing DNA on silicon instead of on traditional 96-well plastic plates, theplatform overcomes the current inefficiencies of synthetic DNA production and enables cost-effective, rapid, high-quality, and high-throughput synthetic gene production.
Following the 2016 acquisition of Genome Compiler Corporation, a provider of software for genetic engineers and molecular and synthetic biologists, the company establisheda researchand development center in Tel Aviv. This acquisition soughtto leverage Genome Compiler's technology to drive a digital product portfolio, including an eCommerce solution with gene design capabilities. Theproducts will enable Twist Bioscience's customers to reimagine their research by providing seamless integration of the design and build of their synthetic DNA.